Bradycor bradykinin antagonist: Began a Phase II trial in 160 patients. End points will be improved intracranial pressure and outcome on the Glasgow Coma Score,

Cortech Inc. (CRTQ), Denver
Product: Bradycor

Read the full 65 word article

How to gain access

Continue reading with a
two-week free trial.